Gangliotetraosylceramide (GA1)

Gangliotetraosylceramide, more commonly referred to as Asialo-GM1 (GA1), is a neutral glycosphingolipid that serves as a vital component of the plasma membrane in specific cell types. It is characterized by the carbohydrate structure Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-Ceramide and is notably expressed on the surface of Natural Killer (NK) cells, activated macrophages, and certain T-cell subsets (PMID: 6414371). Biologically, it functions as a scaffold for cell-surface signaling and as a recognition molecule for cell-to-cell interactions. In pharmacological research, it is primarily targeted by anti-asialo-GM1 antibodies to achieve systemic depletion of NK cells in vivo, allowing researchers to study the role of innate immunity in oncology and infectious disease models (PMID: 15124010). In a clinical and pathological context, Gangliotetraosylceramide acts as a high-affinity receptor for various pathogens, including Pseudomonas aeruginosa and Rotavirus, facilitating their adherence to respiratory and intestinal epithelia (PMID: 9453616). Furthermore, the molecule is implicated in the pathogenesis of autoimmune disorders; specifically, anti-GA1 autoantibodies are frequently detected in patients with variants of Guillain-Barré syndrome and other acute peripheral neuropathies (PubChem CID: 11232860). While not currently a target for traditional small-molecule therapeutics, its role as a tumor-associated antigen and its involvement in pathogen entry make it a significant focus for the development of novel glycobiological interventions and immunotherapies.

Other names

Asialo-GM1Gg4CerGangliotetraosylceramide (Gg4)Gangliotetraosyl-N-hexosylceramideNeutral gangliotetraosylceramide

Antibody-mediated depletion of Natural Killer (NK) cells and activated macrophages via antibody-dependent cellular cytotoxicity (ADCC); pathogen attachment site for bacterial pili and viral proteins.